Electromed, Inc. · AMEX:ELMD
Electromed — Q3 2025 Earnings Presentation
21 slides from Electromed's earnings presentation, May 13, 2025
Slide 1: Electromed, Inc. Investor Presentation
Electromed, Inc. Investor Presentation May 13, 2025 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies Investor Presentation | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this press release constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “estimate,” “expect,” “int
Slide 3: Electromed – Who We Are
Electromed – Who We Are Electromed, Inc. is a Key Stats: growing medical device company Headquarters: Ticker: Established: focused on airway New Prague, MN ELMD 1992 management to help people around the world breathe better, Annual Revenue: Market Cap: Share Count: $61.5M $204M 8.6M stay healthier,
Slide 4: Electromed Highlights
Electromed Highlights 29% Net Income CAGR* $61.5 » Growing and profitable medical technology company $54.7 » A leader in the large and expanding airway clearance $48.1 market $41.7 » The SmartVest® Airway Clearance System’s $35.8 High Frequency Chest Wall Oscillation (“HFCWO”) technology supported b
Slide 5: What is Bronchiectasis (BE)?
What is Bronchiectasis (BE)? » Irreversible lung condition characterized by abnormal widening of one or more of the bronchi (airways) » Repeated episodes of pulmonary inflammation and infection leads to mucus accumulating in the airways » Mean prevalence of bronchiectasis in patients with COPD is 54
Slide 6: U.S. Market: Large, Growing, Underpenetrated
U.S. Market: Large, Growing, Underpenetrated ~127K Estimated HFCWO Estimated Net HFCWO ADOPTED 1 bronchiectasis Bronchiectasis ~824K penetration, treated prevalence, U.S. BE Diagnosed1 population1 DIAGNOSED1 Bronchiectasis HFCWO penetration ~15%1 4.1 million Estimated U.S. Diagnosed BE bronchiectasi
Slide 7: How is Bronchiectasis Treated?
How is Bronchiectasis Treated? Antibiotics, Anti-Inflammatories, Airway Clearance Investor Presentation | 7
Slide 8: How is Bronchiectasis Treated?
How is Bronchiectasis Treated? HFCWO Therapy – Mimics Manual CPT Investor Presentation | 8
Slide 9: SmartVest Clearway®
SmartVest Clearway® HFCWO Designed with the Patient in Mind An Enhanced Patient Experience Sleek and light weight generator Intuitive user interface for better patient adherence More portable and easier for travel SmartVest® has a well-established reimbursement code from CMS – E0483; Electromed has
Slide 10: SmartNotes™ Patient Progress Report
SmartNotes™ Patient Progress Report Patient Outcomes and Treatment Progress to Physicians SmartNotes combine patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management » TeleRespiratory Services: A team of Respiratory Therapists stay connec
Slide 11: Clinical Evidence
Clinical Evidence Electromed has Published Studies Showing Effectiveness of HFCWO to Treat Bronchiectasis Therapy with Therapy with SmartVest® HFCWO demonstrated key significantly decreased health outcomes improved exacerbations requiring in post- compared to pre- hospitalization, antibiotic index p
Slide 12: Direct-to-Patient Model
Direct-to-Patient Model Drives Attractive Margin Profile Traditional Medical Manufacturer $ DME $ Patient Equipment Channel vs. Direct-to-Patient Electromed $$ Patient Distribution (Electromed) ELMD expects gross margins in the mid-70s and improving with the SmartVest® Clearway® Investor Presentatio
Slide 13: Net Revenue Breakdown - $61.5M (TTM ended 3/31/2025)
Net Revenue Breakdown - $61.5M (TTM ended 3/31/2025) By Setting Homecare By Homecare Qualified Payer Referral Volume 1% 5% 2% 2% 20% 46% 3% 52% 75% 94% Home Care1 Medicare Bronchiectasis Hospitals Commercial/Other2 Cystic Fibrosis Other Medicaid Neuromuscular Other 1.Includes $2.6 million from home
Slide 14: Growth Strategy
Growth Strategy How will Electromed Increase Market Share? Continued sales force expansion along with complementary infrastructure investments Increase brand awareness and revenue with direct-to-consumer and physician marketing Market development to improve diagnosis rates and evidence to support th
Slide 15: Long-Term Objectives
Long-Term Objectives Electromed is committed to delivering long-term profitable growth Double-digit Revenue Growth Increase market share Deeper penetration of current SmartVest prescribers Operating Margin Improvement Operating leverage as revenue increases Investor Presentation | 15
Slide 16: Why Invest?
Why Invest? Large, expanding Clinically proven Broad Consistent High gross chronic technology payor coverage double-digit margins, lung diseases organic robust cash flow market revenue growth and expanding operating leverage Investor Presentation | 16
Slide 17: Management Incentives Aligned w/Investors
Management Incentives Aligned w/Investors CEO Incentive Reward based on increasing total shareholder return. Management’s Incentive Compensation Focused solely on delivering financial results. Investor Presentation | 17
Slide 18: Performance vs. Russell Medical Index
Performance vs. Russell Medical Index (TTM and as of 3/31/2025 Results) RUS Metric ELMD ME Sales Growth 15.0% > 12.8% Gross Margin 77.6% > 53.7% Operating Margin 14.6% > 0.04% Investor Presentation | 18
Slide 19: Contacts
Jim Cunniff, President & CEO Mike Cavanaugh (952) 758-9299 (617) 877-8641 jcunniff@Electromed.com mike.cavanaugh@westwicke.com Brad Nagel, CFO Maren Czura (952) 758-9299 (332) 242-4365 bnagel@Electromed.com maren.czura@westwicke.com Investor Presentation | 19
Slide 20: Appendix
APPENDIX Investor Presentation | 20
Slide 21: Financial Highlights
Financial Highlights Financial Summary Three months ended Year Ended Mar 31, 2024 Mar 31, 2025 June 30, 2023 June 30, 2024 TTM Mar 31, 2025 (in $ millions, except shares amounts) (unaudited) (unaudited) (unaudited) Revenues $13.9 $15.7 $48.1 $54.7 $61.5 Gross Profit $10.4 $12.2 $36.5 $41.7 $47.6 Gro